OFFICIAL STATEMENTS

Press releases

26 September 2023

Successful EUR 3 million financing round allows ABSCINT to start Phase II Clinical Trials

20 February 2023

ABSCINT and the VUB announce a Notice of Allowance for their U.S. Patent covering diagnostic applications of its single-domain antibody labelled with radioisotopes for PET/CT imaging of HER2 cancer lesions

5 December 2022

ABSCINT closed a new financing round to pursue development of single-domain antibody-based diagnostics

Our solution is available

Experience the future of diagnostics with ABSCINT. Illuminate HER2 expression for transformative precision in breast cancer and beyond

Get Our Solution Today

What we do

Who we are

© 2024 ABSCINT